See more : Franco-Nevada Corporation (FNV.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Central Securities Corp. (CET) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Central Securities Corp., a leading company in the Asset Management industry within the Financial Services sector.
You may be interested
- Citizen Watch Co., Ltd. (7762.T) Income Statement Analysis – Financial Results
- Fangzhou Inc (6086.HK) Income Statement Analysis – Financial Results
- Ever Harvest International Group Inc. (TLGN) Income Statement Analysis – Financial Results
- PT Saraswanti Indoland Development Tbk (SWID.JK) Income Statement Analysis – Financial Results
- Steed Oriental (Holdings) Company Limited (8277.HK) Income Statement Analysis – Financial Results
Central Securities Corp. (CET)
About Central Securities Corp.
Central Securities Corp. is a publicly owned investment manager. The firm invests in the public equity markets of the United States. It also invests on bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks and corporations. Central Securities Corp. was founded on October 1, 1929 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 230.44M | -152.65M | 360.31M | 79.89M | 256.96M | -28.49M | 174.85M | 118.04M | -12.61M | 34.50M | 147.86M | 17.45M | 3.05M | 109.47M | 10.26M | 12.05M | 11.64M | 10.41M | 8.67M | 4.85M | 4.05M | 4.85M | 5.84M | 7.85M | 6.77M | 7.00M | 6.14M | 6.03M |
| Cost of Revenue | 4.80M | 4.63M | 5.57M | 4.69M | 4.57M | 4.44M | 4.25M | 4.14M | 3.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 225.64M | -157.28M | 354.74M | 75.21M | 252.40M | -32.92M | 170.59M | 113.90M | -15.77M | 34.50M | 147.86M | 17.45M | 3.05M | 109.47M | 10.26M | 12.05M | 11.64M | 10.41M | 8.67M | 4.85M | 4.05M | 4.85M | 5.84M | 7.85M | 6.77M | 7.00M | 6.14M | 6.03M |
| Gross Profit Ratio | 97.92% | 103.03% | 98.45% | 94.13% | 98.22% | 115.58% | 97.57% | 96.49% | 125.09% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | -2.16 | 3.40 | 1.50 | 5.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.63M | 5.82M | 6.53M | 5.98M | 5.77M | 5.61M | 5.49M | 5.25M | 4.27M | 4.22M | 4.55M | 4.34M | 3.63M | 3.50M | 3.51M | 3.44M | 3.57M | 2.93M | 2.77M | 2.52M | 2.09M | 2.06M | 2.22M | 2.23M | 2.06M | 2.06M | 2.00M | 1.60M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.63M | 5.82M | 6.53M | 5.98M | 5.77M | 5.61M | 5.49M | 5.25M | 4.27M | 4.22M | 4.55M | 4.34M | 3.63M | 3.50M | 3.51M | 3.44M | 3.57M | 2.93M | 2.77M | 2.52M | 2.09M | 2.06M | 2.22M | 2.23M | 2.06M | 2.06M | 2.00M | 1.60M |
| Other Expenses | 223.81M | 201.47K | 203.13K | 202.75K | 182.21K | 182.93K | 147.27K | 155.99K | 159.52K | 156.20K | 144.17K | 163.03K | 655.22K | 667.07K | 370.00K | 360.00K | 260.00K | 210.00K | 210.00K | 260.00K | 230.00K | 210.00K | 280.00K | 210.00K | 190.00K | 160.00K | 180.00K | 180.00K |
| Operating Expenses | 230.44M | 6.02M | 6.73M | 6.18M | 5.95M | 5.79M | 5.64M | 5.40M | 4.43M | 4.38M | 4.69M | 4.51M | 4.29M | 4.17M | 3.88M | 3.80M | 3.83M | 3.14M | 2.98M | 2.78M | 2.32M | 2.27M | 2.50M | 2.44M | 2.25M | 2.22M | 2.18M | 1.78M |
| Cost & Expenses | 230.44M | 6.02M | 6.73M | 6.18M | 5.95M | 5.79M | 5.64M | 5.40M | 4.43M | 4.38M | 4.69M | 4.51M | 4.29M | 4.17M | 3.88M | 3.80M | 3.83M | 3.14M | 2.98M | 2.78M | 2.32M | 2.27M | 2.50M | 2.44M | 2.25M | 2.22M | 2.18M | 1.78M |
| Interest Income | 3.86M | 905.87K | 5.60K | 199.06K | 829.96K | 785.44K | 419.77K | 119.26K | 19.58K | 14.11K | 10.79K | 0.00 | 0.00 | 4.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.66M | 43.58M | 42.12M | 36.47M | 31.67M | 25.10M | 24.76M | 22.87M | 13.66M | 65.92M | 43.21M | 22.91M | 30.13M | 18.15M |
| Depreciation & Amortization | 218.28K | 180.68K | 394.20K | 7.32K | 3.73K | 4.40K | 6.31K | 8.90K | 10.66K | 29.34K | 47.67K | 46.69K | 46.52K | 47.51K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 92.52M | 159.41M | -139.65M | -31.06M | 100.83M | 178.95M | 73.81M | 119.30M | 89.01M |
| EBITDA | 223.85M | -158.66M | 353.97M | 73.72M | 251.02M | -34.27M | 169.21M | 112.64M | -17.03M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 124.31M | -209.88M | 54.65M | 129.85M | 99.79M | 94.60M | 161.15M | -137.06M | -27.72M | 106.23M | 183.47M | 78.59M | 123.27M | 93.26M |
| EBITDA Ratio | 97.14% | 103.94% | 98.13% | 92.28% | 97.69% | 120.32% | 96.78% | 95.43% | 135.09% | 87.40% | 96.86% | 74.43% | -39.28% | 96.24% | 1,211.60% | -1,379.92% | 831.53% | 1,247.36% | 1,150.98% | 1,950.52% | 3,979.01% | -2,825.98% | -474.66% | 1,353.25% | 2,710.04% | 1,122.71% | 2,007.65% | 1,546.60% |
| Operating Income | 223.64M | -158.67M | 353.58M | 73.72M | 251.01M | -34.28M | 169.21M | 112.64M | -17.04M | 30.13M | 143.17M | 12.94M | -1.24M | 105.31M | 6.38M | 8.25M | 7.82M | 7.27M | 5.68M | 2.08M | 1.74M | 2.59M | 3.34M | 5.40M | 4.52M | 4.78M | 3.97M | 4.25M |
| Operating Income Ratio | 97.05% | 103.95% | 98.13% | 92.27% | 97.68% | 120.34% | 96.77% | 95.42% | 135.17% | 87.32% | 96.83% | 74.16% | -40.80% | 96.19% | 62.18% | 68.46% | 67.18% | 69.84% | 65.51% | 42.89% | 42.96% | 53.40% | 57.19% | 68.79% | 66.77% | 68.29% | 64.66% | 70.48% |
| Total Other Income/Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 110.17M | -218.21M | 46.75M | 86.01M | 62.34M | 67.42M | 134.65M | -162.52M | -44.72M | 34.91M | 135.74M | 50.90M | 89.17M | 70.86M |
| Income Before Tax | 223.64M | -158.67M | 353.58M | 73.72M | 251.01M | -34.28M | 169.21M | 112.64M | -17.04M | 30.13M | 143.17M | 12.94M | -1.24M | 105.31M | 116.55M | -209.96M | 54.57M | 93.28M | 68.02M | 69.50M | 136.39M | -159.93M | -41.38M | 40.31M | 140.26M | 55.68M | 93.14M | 75.11M |
| Income Before Tax Ratio | 97.05% | 103.95% | 98.13% | 92.27% | 97.68% | 120.34% | 96.77% | 95.42% | 135.17% | 87.32% | 96.83% | 74.16% | -40.80% | 96.19% | 1,135.96% | -1,742.41% | 468.81% | 896.06% | 784.54% | 1,432.99% | 3,367.65% | -3,297.53% | -708.56% | 513.50% | 2,071.79% | 795.43% | 1,516.94% | 1,245.61% |
| Income Tax Expense | 0.00 | 2.00 | 7.00 | 2.00 | 4.00 | 1.00 | 1.00 | 3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 117.83M | -174.63M | 88.87M | 122.48M | 94.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 223.64M | -158.67M | 353.58M | 73.72M | 251.01M | -34.28M | 169.21M | 112.64M | -17.04M | 30.13M | 143.17M | 12.94M | -1.24M | 105.31M | 116.55M | -209.96M | 54.57M | 93.28M | 68.02M | 69.50M | 136.39M | -159.93M | -41.38M | 40.31M | 140.26M | 55.68M | 93.14M | 75.11M |
| Net Income Ratio | 97.05% | 103.95% | 98.13% | 92.27% | 97.68% | 120.34% | 96.77% | 95.42% | 135.17% | 87.32% | 96.83% | 74.16% | -40.80% | 96.19% | 1,135.96% | -1,742.41% | 468.81% | 896.06% | 784.54% | 1,432.99% | 3,367.65% | -3,297.53% | -708.56% | 513.50% | 2,071.79% | 795.43% | 1,516.94% | 1,245.61% |
| EPS | 7.88 | -5.81 | 13.47 | 2.81 | 9.70 | -1.37 | 6.80 | 4.60 | -0.69 | 1.15 | 5.95 | 0.51 | -0.05 | 4.62 | 5.16 | -9.40 | 2.55 | 4.48 | 3.28 | 3.47 | 6.93 | -8.27 | -2.19 | 2.23 | 8.32 | 3.74 | 6.56 | 5.20 |
| EPS Diluted | 7.88 | -5.81 | 12.97 | 2.81 | 9.70 | -1.37 | 6.80 | 4.60 | -0.69 | 1.15 | 5.95 | 0.51 | -0.05 | 4.62 | 5.16 | -9.40 | 2.55 | 4.48 | 3.28 | 3.47 | 6.93 | -8.27 | -2.19 | 2.23 | 8.32 | 3.74 | 6.56 | 5.20 |
| Weighted Avg Shares Out | 28.39M | 27.31M | 26.25M | 26.24M | 25.89M | 25.02M | 24.88M | 24.49M | 24.70M | 26.20M | 24.06M | 25.37M | 23.01M | 22.78M | 22.59M | 22.33M | 21.39M | 20.82M | 20.76M | 20.02M | 19.69M | 19.34M | 18.91M | 18.10M | 16.85M | 14.87M | 14.19M | 14.44M |
| Weighted Avg Shares Out (Dil) | 28.39M | 27.31M | 27.27M | 26.24M | 25.89M | 25.02M | 24.88M | 24.49M | 24.70M | 26.20M | 24.06M | 25.37M | 23.01M | 22.78M | 22.59M | 22.33M | 21.39M | 20.82M | 20.76M | 20.02M | 19.69M | 19.34M | 18.91M | 18.10M | 16.85M | 14.87M | 14.19M | 14.44M |
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference call today at 1:30 PM CET (8:30 AM ET) Regulated...
Webcast details for Orrön Energy's Q3 presentation
Orrön Energy AB (“Orrön Energy”) will publish its financial report for the third quarter 2024 on Wednesday, 6 November 2024 at 07:30 CET, followed by a webcast at 14.00 CET.
Viridien Announces its Q3 Financial Results on Thursday 31st October 2024, after Market Close
Paris, France – October 17th, 2024 Viridien, formerly CGG, will announce its third quarter 2024 financial results on Thursday, October 31st, after market close. The press release and the presentation will be made available on our website www.viridiengroup.com at 5:45...
The ABCs On CEFs
Closed-end funds offer unique advantages like fixed share numbers, no redemption liquidity issues, and exposure to hard-to-access asset classes, enhancing portfolio diversification. CEFs can trade at significant discounts or premiums to NAV due to supply and demand, unlike mutual funds...
Invitation - presentation of Husqvarna Group's report for the third quarter 2024
STOCKHOLM , Oct. 8, 2024 /PRNewswire/ -- Husqvarna Group will publish its third quarter results on October 23, 2024, at approximately 07:00 CET. A combined webcast and conference call hosted by CEO Pavel Hajman and CFO Terry Burke will be...
Correction of a Release from 05.09.2024 17:45 CET/CEST - 2CRSi SA: 2CRSi Announces the Production of its New Godì 1.8ER-NV8 Servers Equipped with 8x NVIDIA H200 SXM5 GPUs, with an Estimated Market Value of 288 million USD*
STRASBOURG, FRANCE / ACCESSWIRE / September 6, 2024 / 2CRSi (ISIN: FR0013341781), a designer and manufacturer of high-performance, energy-efficient servers, announces that it has placed orders with its suppliers for the components required to manufacture its new HGX server, the...
CET: A Steady Eddy That Outperforms
The Central Securities Corporation is a boring but profitable equity CEF that has outperformed the S&P 500 in the past year, with the same volatility. CET's emphasis on holding its top holdings for extended periods, including the Plymouth Rock Company,...
Hafnia's H1 / Q2 2024 Financial Results Presentation to Be Held on 23 August 2024
SINGAPORE--(BUSINESS WIRE)--Hafnia Limited (“Hafnia”, the “Company”, OSE ticker code: “HAFNI”, NYSE ticker code “HAFN”) will release its H1 / Q2 2024 results at approximately 07:30 CET on 23 August 2024. In connection with this release, Hafnia will hold an investor...
Central Securities Corporation Releases Report to Stockholders
NEW YORK--(BUSINESS WIRE)--Central Securities Corporation (NYSE American: CET), a closed-end investment company, today released its Report to Stockholders for the six months ended June 30, 2024. Figures as of June 30, 2024 compared with those of one year ago, are...
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
Press Release – No. 8 / 2024 Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results Copenhagen, Denmark, August 12, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no.
Source: https://incomestatements.info
Category: Stock Reports